Exelixis (EXEL) Tops Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Exelixis (EXEL) Tops Q1 EPS by 4c

Exelixis (EXEL) PT Lowered to $25 at Cowen

May 2, 2019 8:48 AM EDT

Cowen analyst Yaron Werber lowered the price target on Exelixis (NASDAQ: EXEL) to $25.00 (from $29.00) while maintaining a Outperform rating.

... More

Exelixis (EXEL) Commences Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab

May 1, 2019 5:25 PM EDT

Exelixis, Inc. (NASDAQ: EXEL) today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with nivolumab (Opdivo®) and ipilimumab (Yervoy®) versus nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium. The primary endpoint of the trial is... More